Brokerages expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to announce earnings per share (EPS) of ($1.03) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.10) to ($0.95). Atara Biotherapeutics posted earnings of ($0.88) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 17%. The firm is expected to report its next quarterly earnings report on Friday, November 3rd.

On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.24) to ($3.75). For the next fiscal year, analysts anticipate that the company will report earnings of ($4.60) per share, with EPS estimates ranging from ($5.25) to ($3.94). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05).

A number of research analysts have recently commented on ATRA shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Canaccord Genuity reissued a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a report on Monday, September 11th. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Finally, ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $25.50.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Atara Biotherapeutics, Inc. (ATRA) to Announce -$1.03 Earnings Per Share” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/23/zacks-brokerages-anticipate-atara-biotherapeutics-inc-atra-to-announce-1-03-earnings-per-share.html.

In related news, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $15.54, for a total transaction of $68,376.00. Following the sale, the chief executive officer now owns 737,767 shares of the company’s stock, valued at approximately $11,464,899.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $16.94, for a total value of $47,432.00. Following the sale, the chief executive officer now directly owns 731,859 shares in the company, valued at approximately $12,397,691.46. The disclosure for this sale can be found here. Insiders have sold a total of 53,909 shares of company stock worth $810,518 in the last three months. 16.10% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its holdings in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares in the last quarter. Voya Investment Management LLC increased its stake in Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 610 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Atara Biotherapeutics by 16.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,682 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 4,293 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Atara Biotherapeutics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after acquiring an additional 13,952 shares during the last quarter. 82.95% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics (NASDAQ:ATRA) traded up 0.64% during trading on Friday, reaching $15.65. The company had a trading volume of 192,906 shares. The firm’s market capitalization is $478.25 million. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00. The stock has a 50 day moving average price of $14.71 and a 200 day moving average price of $15.84.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.